Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000571186 | SCV000676258 | pathogenic | Hereditary cancer-predisposing syndrome | 2016-07-09 | criteria provided, single submitter | clinical testing | The c.165-3_165delAAGG pathogenic mutation, located at the 5' end of coding exon 3 of the PTEN gene, results from a deletion of 3 intronic nucleotides and 1 exonic nucleotide at positions 165-3 to 165. This deletion spans the native splice acceptor sequence and is predicted to abolish this site by the BDGP and ESEfinder in silico splicing models. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |